Tech Company Financing Transactions

Quell Therapeutics Funding Round

Quell Therapeutics closed a $156 million Series B funding round on 11/30/2021. Investors included Fidelity Management & Research Company, JEITO and Ridgeback Capital.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B

Fidelity Management & Research Company (Lead Investor)

JEITO (Lead Investor) (Rachel Mears)

Ridgeback Capital (Lead Investor) (Jeffrey Long-McGie)

SV Health Investors (Lead Investor) (Houman Ashrafian)

British Patient Capital

Janus Henderson Investors

Monashee Investment Management

Point72 Ventures

Syncona (Martin Murphy)

Tekla Capital Management

Proceeds Purpose
Proceeds from the financing will be used to: Advance Quell's pipeline in core therapeutic areas of transplantation, neuroinflammatory diseases and autoimmune diseases.

Company Information

Company Status
Private & Independent
Mailing Address
Translation & Innovation Hub 84 Wood Ln.
London, W12 OBZ
Email Address
At Quell we seek to deliver truly innovative, life-changing therapies for our patients. Our vision as a company is to build a major global biopharmaceutical company bringing transformational and valued therapies for a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation, based on modular engineered Tregs.
Quell Therapeutics LinkedIn Company Profile
Social Media
Quell Therapeutics Company Twitter Account
Company News
Quell Therapeutics News
Quell Therapeutics on Facebook
Quell Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Iain McGill
  Iain McGill LinkedIn Profile  Iain McGill Twitter Account  Iain McGill News  Iain McGill on Facebook
Chief Medical Officer
Dominik Hartl
  Dominik Hartl LinkedIn Profile  Dominik Hartl Twitter Account  Dominik Hartl News  Dominik Hartl on Facebook
Chief Scientific Officer
Tracey Lodie
  Tracey Lodie LinkedIn Profile  Tracey Lodie Twitter Account  Tracey Lodie News  Tracey Lodie on Facebook
Elmar Jaeckel
  Elmar Jaeckel LinkedIn Profile  Elmar Jaeckel Twitter Account  Elmar Jaeckel News  Elmar Jaeckel on Facebook
Giovanna Lombardi
  Giovanna Lombardi LinkedIn Profile  Giovanna Lombardi Twitter Account  Giovanna Lombardi News  Giovanna Lombardi on Facebook
Emma Morris
  Emma Morris LinkedIn Profile  Emma Morris Twitter Account  Emma Morris News  Emma Morris on Facebook
Hans Stauss
  Hans Stauss LinkedIn Profile  Hans Stauss Twitter Account  Hans Stauss News  Hans Stauss on Facebook
Vice President
Jodie Albutt
  Jodie Albutt LinkedIn Profile  Jodie Albutt Twitter Account  Jodie Albutt News  Jodie Albutt on Facebook
Vice President
Marc Martinez-Llordella
  Marc Martinez-Llordella LinkedIn Profile  Marc Martinez-Llordella Twitter Account  Marc Martinez-Llordella News  Marc Martinez-Llordella on Facebook
VP - Bus. Development
Luke Henry
  Luke Henry LinkedIn Profile  Luke Henry Twitter Account  Luke Henry News  Luke Henry on Facebook
VP - Finance
Mark Fox
  Mark Fox LinkedIn Profile  Mark Fox Twitter Account  Mark Fox News  Mark Fox on Facebook
VP - Product Management
Bernd Schmidt
  Bernd Schmidt LinkedIn Profile  Bernd Schmidt Twitter Account  Bernd Schmidt News  Bernd Schmidt on Facebook
VP - R & D
Nathalie Belmonte
  Nathalie Belmonte LinkedIn Profile  Nathalie Belmonte Twitter Account  Nathalie Belmonte News  Nathalie Belmonte on Facebook



Browse more venture capital transactions:

Prev: 11/30/2021: Forest venture capital transaction
Next: 11/30/2021: Motorway venture capital transaction


Share this article


About Database of VC Transactions

We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary